The stock of Mind Medicine Inc (MNMD) has seen a -7.77% decrease in the past week, with a -10.89% drop in the past month, and a -26.72% decrease in the past quarter. The volatility ratio for the week is 5.45%, and the volatility levels for the past 30 days are at 7.08% for MNMD. The simple moving average for the past 20 days is -9.72% for MNMD’s stock, with a 29.82% simple moving average for the past 200 days.
Is It Worth Investing in Mind Medicine Inc (NASDAQ: MNMD) Right Now?
The 36-month beta value for MNMD is also noteworthy at 0.95. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MNMD is 27.40M, and at present, short sellers hold a 23.29% of that float. The average trading volume of MNMD on June 20, 2024 was 1.58M shares.
MNMD) stock’s latest price update
The stock price of Mind Medicine Inc (NASDAQ: MNMD) has dropped by -1.09 compared to previous close of 7.32. Despite this, the company has seen a fall of -7.77% in its stock price over the last five trading days. businesswire.com reported 2024-06-20 that NEW YORK–(BUSINESS WIRE)—- $MNMD–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
Analysts’ Opinion of MNMD
Many brokerage firms have already submitted their reports for MNMD stocks, with Robert W. Baird repeating the rating for MNMD by listing it as a “Outperform.” The predicted price for MNMD in the upcoming period, according to Robert W. Baird is $27 based on the research report published on May 29, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see MNMD reach a price target of $20. The rating they have provided for MNMD stocks is “Outperform” according to the report published on April 15th, 2024.
Canaccord Genuity gave a rating of “Buy” to MNMD, setting the target price at $9 in the report published on December 05th of the previous year.
MNMD Trading at -17.04% from the 50-Day Moving Average
After a stumble in the market that brought MNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.75% of loss for the given period.
Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 5.45%, as shares sank -13.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.86% lower at present.
During the last 5 trading sessions, MNMD fell by -7.64%, which changed the moving average for the period of 200-days by +76.40% in comparison to the 20-day moving average, which settled at $7.96. In addition, Mind Medicine Inc saw 97.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MNMD starting from Barrow Robert, who sale 16,519 shares at the price of $9.50 back on Mar 25 ’24. After this action, Barrow Robert now owns 580,202 shares of Mind Medicine Inc, valued at $156,930 using the latest closing price.
Karlin Dan, the Chief Medical Officer of Mind Medicine Inc, sale 6,578 shares at $9.50 during a trade that took place back on Mar 25 ’24, which means that Karlin Dan is holding 358,452 shares at $62,491 based on the most recent closing price.
Stock Fundamentals for MNMD
Current profitability levels for the company are sitting at:
- -19.68 for the present operating margin
- 0.39 for the gross margin
The net margin for Mind Medicine Inc stands at -25.9. The total capital return value is set at -0.45. Equity return is now at value -76.79, with -58.14 for asset returns.
Based on Mind Medicine Inc (MNMD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.71. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 112.01.
Currently, EBITDA for the company is -90.7 million with net debt to EBITDA at 2.59. When we switch over and look at the enterprise to sales, we see a ratio of 57.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.91.
Conclusion
In summary, Mind Medicine Inc (MNMD) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
